Frontline Ruxolitinib Therapy for Steroid-Refractory cGVHD

Ruxolitinib Data and Clinical Experience

This segment focuses on the REACH-3 study data for ruxolitinib, demonstrating significant advantages over best available therapy:

• Median failure-free survival: 38 months vs 6 months
• 12-month failure-free survival probability: 64% vs 30%
• Duration of response was not reached in the ruxolitinib group vs 6.5 months in the control arm

The panelists share their clinical preferences, noting they typically use ruxolitinib as their first second-line agent due to better tolerability compared with ibrutinib. They discuss managing cytopenia adverse effects and the occasional need to balance ruxolitinib dosing with steroid tapering. The panelists note less real-world use of ibrutinib due to adverse effects, particularly arrhythmias.